Studying Triptorelin Treatment to Reduce Pain and Hormone Levels in Women with Endometriosis Cysts Aged 18 to 40

What this Trial Is About

Endometriosis is a long-lasting condition affecting 10-15% of women of childbearing age, commonly causing pelvic pain. Researchers are evaluating the effects of the drug triptorelin, a treatment approved in Indonesia for endometriosis symptoms, to compare dosing intervals and their impact on pain and hormone levels. This study aims to assess whether extending the dose interval can reduce side effects and improve patient adherence while effectively managing symptoms. Participants will be divided into two groups receiving triptorelin over an 18-week period. The first group will receive three doses two before surgery at baseline and week 6, and one after surgery at week 12. The second group will receive a single dose after surgery at week 12. The study is open label and non-randomized, with visits every six weeks to monitor treatment effects. During the study, participants will have their pain levels measured using a visual analogue scale VAS at baseline, week 6, week 12 before surgery, and week 18. Blood tests will assess Anti Mullerian Hormone AMH and estradiol levels at baseline and week 12. Additionally, surgical evaluation will assess the condition of the uterus and cysts. This approach allows researchers to observe hormone changes, pain improvement, and physical condition related to endometriosis treatment over time.

Effect GnRH Agonist Administration in Endometriosis Cyst Patients